paronychia/мучнина

Веза се чува у привремену меморију

Изаберите тип сортирања

13 резултати

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Purpose Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Advances in the understanding of the mechanisms involved in oncogenesis have led to the development of so-called targeted therapies such as epidermal growth factor receptor (EGFR) inhibitors, which take on an increasingly important role in the management of cancer. These treatments have

Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND The management of skin toxicity is crucial for efficient afatinib treatment, but the role of tetracycline class antibiotics (TCs) in managing these rashes is relatively unknown. METHODS We reviewed the clinical records of patients who were administered afatinib for the treatment of

Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Prompted by recent demonstrations that all-trans-retinoic acid (all-trans-RA) had efficacy in acute promyelocytic leukemia, a phase I trial of all-trans-RA was conducted to establish the maximum-tolerated dose (MTD) before phase II testing. METHODS Forty patients with a histologic or

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M. We evaluated safety, pharmacokinetics and efficacy of

A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Terbinafine is a commonly prescribed antifungal agent used in the treatment of trichophytic onychomycosis and chronic cutaneous mycosis that are resistant to other treatments. This case report highlights a rarely documented but important adverse hepatic reaction that was caused by the use of oral

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The safety, tolerability, and pharmacokinetic (PK) interactions of MK-0646 in combination with cetuximab and irinotecan were investigated in Japanese patients with advanced colorectal cancer. METHODS Twenty patients were treated in the following study arms in combination with cetuximab and

FDA drug approval summary: panitumumab (Vectibix).

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

On September 27, 2006, the U.S. Food and Drug Administration granted approval to panitumumab (Vectibix, Amgen, Inc., Thousand Oaks, CA) for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma with disease progression on or following

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration initially granted accelerated approval to gefitinib but

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + 3 dose

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Purpose: Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1.We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Tyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various malignancies. Imatinib was the first to be introduced into clinical oncology, and it was followed by drugs such as gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib. Although they share the same mechanism of

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима